These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 21076461)

  • 1. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
    Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
    Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.
    Lacroix-Triki M; Geyer FC; Lambros MB; Savage K; Ellis IO; Lee AH; Reis-Filho JS
    Mod Pathol; 2010 Nov; 23(11):1438-48. PubMed ID: 20693983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
    Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
    Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
    Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.
    Garcia-Rostan G; Camp RL; Herrero A; Carcangiu ML; Rimm DL; Tallini G
    Am J Pathol; 2001 Mar; 158(3):987-96. PubMed ID: 11238046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
    Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
    PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and significance of Wnt signaling components and their target genes in breast carcinoma.
    He Y; Liu Z; Qiao C; Xu M; Yu J; Li G
    Mol Med Rep; 2014 Jan; 9(1):137-43. PubMed ID: 24190141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
    Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
    Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast.
    Hayes MJ; Thomas D; Emmons A; Giordano TJ; Kleer CG
    Clin Cancer Res; 2008 Jul; 14(13):4038-44. PubMed ID: 18593979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
    Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
    Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
    PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.
    Jayaraj P; Sen S; Sharma A; Chosdol K; Kashyap S; Rai A; Pushker N; Bajaj MS; Ghose S
    Br J Dermatol; 2012 Sep; 167(3):583-90. PubMed ID: 22458737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
    López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
    Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
    Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.